STAAR Surgical Releases Shareholder Letter
STAAR Surgical Releases Update in New Shareholder Letter STAAR Surgical Company the global leader in phakic intraocular lenses (IOLs) and maker of the EVO family of Implantable Collamer® Lenses (EVO ICL™), issued a Shareholder Letter on March 3 following market…
AN2 Therapeutics Moves Oral Epetraborole into Phase 2 for Polycythemia Vera
AN2 Therapeutics, Inc. Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics derived from its proprietary boron chemistry platform, today announced plans…
Progeria Research Foundation and Forge Biologics Partner to Strengthen Gene Therapy Development for Children
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and…
Delcath Systems Reports CHOPIN Clinical Trial Results Published in The Lancet Oncology
Delcath Systems Reports Publication of CHOPIN Clinical Trial Findings in The Lancet Oncology Delcath Systems, Inc. an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the full results from the…
Seaport and Monash Secure Up to $15M ARPA-H Grant for Oral Gut Lymphatic Therapy
ARPA-H Awards Up to $15 Million to Seaport Therapeutics and Monash Institute to Advance First Oral Therapy Targeting Gut Lymphatic Dysfunction Seaport Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative medicines, has announced that it has been awarded up…
EU Regulatory Reforms and Global Healthcare Innovation Take Center Stage @DIA Europe 2026
EU Regulatory Reforms and Global Healthcare Innovation to Be Central Focus at DIA Europe 2026 DIA, a global non-profit association of life sciences professionals, has announced that DIA Europe 2026 will convene leading voices from across Europe and around the…
National Grange Report Highlights Shift of Rural Health Funds to Urban Hospitals
National Grange Backs New Report Warning of Rural Health Funds Being Redirected to Urban Hospitals The National Grange has expressed strong support for the release of a comprehensive new analysis examining how certain Medicare hospital reclassification policies are diverting critical…
Median Technologies Showcases eyonis LCS, AI-Driven SaMD for Lung Cancer Screening, at ECR
Median Technologies to Highlight eyonis® LCS at ECR 2026 as U.S. Commercial Launch Advances and European CE Marking Decision Nears Median Technologies today announced that it will showcase its AI-powered lung cancer screening solution, eyonis® LCS, at the upcoming European…
Cure Rare Disease and LGMD2L Foundation Partner Gene Therapy for Anoctamin 5 Disease
Strategic $7.65 Million Collaboration Aims to Accelerate Development of a Novel ANO5 Gene Replacement Therapy Toward Clinical Trials Cure Rare Disease (CRD), a nonprofit biotechnology organization dedicated to developing treatments for individuals with rare genetic disorders, today announced a landmark,…
MySpaLive Clarifies Texas Medical Aesthetics Law Amid Misleading 2026 Claims
MySpaLive’s Compliance and Training Framework As conversations continue across the medical aesthetics industry regarding claims that Texas has “closed a med spa loophole” in 2026, MySpaLive is issuing a detailed clarification grounded in statutory authority, legislative history, and current Texas…
SBC Medical Appoints Sheng-FU Hsiao as CTO to Lead AI-Driven Medical Infrastructure
SBC Medical Appoints Sheng-FU Hsiao as Chief Technology Officer to Accelerate AI-Driven Transformation SBC Medical Group Holdings Incorporated (“SBC Medical” or the “Company”), a global provider of comprehensive management and consulting services for medical institutions and clinic networks, has announced…
Biocytogen and IDEAYA Advance Innovative Cancer Therapy with First Dosing of IDE034
First Patient Dosed in Phase 1 Trial of IDE034, a Bispecific B7H3/PTK7 TOP1 ADC Why is the development of new cancer therapies so critical in today’s healthcare landscape? Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and IDEAYA…